Epidemiology and Prevention of Hepatitis B Virus Infection

Overview

Journal Korean J Hepatol

Specialty Gastroenterology

Date 2011 Jul 16

PMID 21757978

Citations 59

Authors

So Young Kwon

Chang Hong Lee

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality. The recognition of the problem led to a worldwide effort to reduce transmission of HBV through routine infant vaccination. HBV infection is the most common cause of chronic liver diseases and hepatocellular carcinoma in Korea. After hepatitis B vaccine era, seroprevalence of hepatits B surface antigen is decreasing, particularly in children. Hepatitis B vaccine is remarkably safe and shows high immunogenicity. Universal childhood immunization with three doses of hepatitis B vaccine in the first year of life is a highly effective method for prevention and control of hepatitis B.

Citing Articles

Unveiling the Silent Crisis Amidst Tackling Hepatitis B in African Prisons - A Public Health Emergency.

Scott G, Aborode A, Adesola R, Hope C, Dipeolu O, Ajibade F Health Sci Rep. 2025; 8(3):e70543.

PMID: 40066240 PMC: 11892014. DOI: 10.1002/hsr2.70543.

The interplay of socio-demographic factors and disease prevalence: insights into malaria, Hepatitis B, and Hepatitis C in Lafia, Nasarawa State, Nigeria.

Aremu D, Maxim A, Aremu S, Aremu D, Terhemen Y, Itodo S J Health Popul Nutr. 2025; 44(1):67.

PMID: 40051006 PMC: 11883923. DOI: 10.1186/s41043-025-00779-5.

Prevalence of hepatitis B virus infection and associated factors among adults intrafamilial household contacts attending antenatal care clinics in the Central Ethiopian region: from pregnant women index cases.

Larebo Y, Anshebo A, Behera S, Gopalan N Virol J. 2025; 22(1):34.

PMID: 39939946 PMC: 11823231. DOI: 10.1186/s12985-025-02633-w.

Review of Albanian studies suggests the need for further efforts to counteract significant hepatitis B virus prevalence.

Jaho J, Kamberi F, Mechili E, Bicaj A, Carni P, Baiocchi L World J Virol. 2024; 13(4):93721.

PMID: 39722761 PMC: 11551693. DOI: 10.5501/wjv.v13.i4.93721.

Knowledge, attitudes, and practices toward preventing and controlling hepatitis B virus infection among pregnant women attending antenatal care at a University Hospital in Central Ethiopia: a cross-sectional study.

Larebo Y, Anshebo A, Behera S, Gopalan N Ther Adv Infect Dis. 2024; 11:20499361241285342.

PMID: 39483814 PMC: 11526330. DOI: 10.1177/20499361241285342.

References

Wainwright R, Bulkow L, Parkinson A, Zanis C, McMahon B . Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. J Infect Dis. 1997; 175(3):674-7. DOI: 10.1093/infdis/175.3.674. View

Seeff L, ZIMMERMAN H, Wright E, Finkelstein J, GREENLEE H, Dietz A . A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology. 1977; 72(1):111-21. View

Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock H, Leyssen M, Jacquet J . Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2009; 28(3):730-6. DOI: 10.1016/j.vaccine.2009.10.074. View

Chisari F, Ferrari C, Mondelli M . Hepatitis B virus structure and biology. Microb Pathog. 1989; 6(5):311-25. DOI: 10.1016/0882-4010(89)90073-9. View

McMahon B, Helminiak C, Wainwright R, Bulkow L, Trimble B, Wainwright K . Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med. 1992; 92(3):254-6. DOI: 10.1016/0002-9343(92)90073-k. View

Hadler S, Margolis H . Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis. 1992; 12:282-308. View

Lebre F, Borchard G, Pedroso de Lima M, Borges O . Progress towards a needle-free hepatitis B vaccine. Pharm Res. 2010; 28(5):986-1012. DOI: 10.1007/s11095-010-0314-4. View

Mangione R, Stroffolini T, Tosti M, Fragapani P, Mele A . Delayed third hepatitis B vaccine dose and immune response. Lancet. 1995; 345(8957):1111-2. DOI: 10.1016/s0140-6736(95)90841-2. View

Alward W, McMahon B, Hall D, Heyward W, Francis D, Bender T . The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis. 1985; 151(4):604-9. DOI: 10.1093/infdis/151.4.604. View

10.

Huang L, Chiang B, Lee C, Lee P, Chi W, Chang M . Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999; 29(3):954-9. DOI: 10.1002/hep.510290349. View

11.

. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996; 45(RR-12):1-35. View

12.

SZMUNESS W, Stevens C, Harley E, Zang E, Oleszko W, William D . Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980; 303(15):833-41. DOI: 10.1056/NEJM198010093031501. View

13.

Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J . Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol. 1992; 14(1):27-30. DOI: 10.1097/00004836-199201000-00007. View

14.

Dienstag J . Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection. Springer Semin Immunopathol. 1981; 3(4):461-72. DOI: 10.1007/BF01951493. View

15.

Beasley R, Hwang L . Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 1984; 4(2):113-21. DOI: 10.1055/s-2008-1040651. View

16.

Andre F . Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989; 87(3A):14S-20S. DOI: 10.1016/0002-9343(89)90525-1. View

17.

Beasley R, Hwang L, Stevens C, Lin C, Hsieh F, Wang K . Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983; 3(2):135-41. DOI: 10.1002/hep.1840030201. View

18.

Hsu H, Lu C, Lee S, Lin S, Chen D . Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis. 1999; 179(2):367-70. DOI: 10.1086/314585. View

19.

Alter M, Margolis H . The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am. 1990; 74(6):1529-41. DOI: 10.1016/s0025-7125(16)30493-x. View

20.

Terrault N, Zhou S, Combs C, Hahn J, Lake J, Roberts J . Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996; 24(6):1327-33. DOI: 10.1002/hep.510240601. View